Vijay Pande, who previously ran Andreessen Horowitz's roughly $4 billion biotech investment practice, has launched a new AI-native venture fund called VZVC with a deliberately smaller footprint.
Instead of placing 30 bets a year, Pande is making fewer, more concentrated investments at the intersection of artificial intelligence and biology. He argues that biology is finally transitioning from a "discovery" science to an "engineering" science, driven by AI tools that can model biological systems at unprecedented scale.
The shift reflects a broader trend of experienced investors leaving large firms to build focused, AI-first funds. Pande's deep expertise in bio-AI positions VZVC to identify companies that leverage machine learning for drug discovery, protein engineering, and synthetic biology.
The fund's smaller size is intentional — Pande believes concentrated conviction bets outperform diversified portfolios in the current AI-biology convergence.
